Skip to main content

Table 3 Incidence of grade ≥ 3 adverse events

From: Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective

Grade ≥ 3 adverse events

Afatinib (%)

Pemetrexed-cisplatin (%)

Neutropenia

0.4

18.0

Fatigue

1.3

12.6

Anaemia

0.4

6.3

Nausea

0.9

3.6

Diarrhoea

14.4

0.0

Rash

16.2

0.0

Vomiting

3.1

2.7

  1. Source: Sequist et al, [6]
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us